Literature DB >> 12015312

Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor.

Anita T Stauffer1, Mascha K Rochat, Bernhard Dick, Felix J Frey, Alex Odermatt.   

Abstract

Inappropriate activation of the mineralocorticoid receptor (MR) results in renal sodium retention and potassium loss in patients with liver cirrhosis. Recent evidence suggested that this MR activation is, at least in part, a result of bile acid-dependent reduction in 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta HSD2) activity, an enzyme preventing cortisol-dependent activation of MR by converting cortisol to cortisone. Here, we investigated the molecular mechanisms underlying bile acid-mediated MR activation. Analysis of urinary bile acids from 12 patients with biliary obstruction revealed highly elevated concentrations of chenodeoxycholic acid (CDCA), cholic acid (CA), and deoxycholic acid (DCA), with average concentrations of 50-80 microm. Although CDCA and DCA both mediated nuclear translocation of MR in the absence of 11 beta HSD2 and steroids in transiently expressing HEK-293 cells, the transcriptional activity of MR was not stimulated. In contrast, CDCA and DCA both inhibited 11 beta HSD2 with IC(50) values of 22 and 38 microm, respectively and caused cortisol-dependent nuclear translocation and increased transcriptional activity of MR. LCA, the bile acid that most efficiently inhibited 11 beta HSD2, was present at very low concentrations in cholestatic patients, whereas the weak inhibitor CA did not cause MR activation. In conclusion, these findings indicate that CDCA, and to a lesser extent DCA, by inhibiting 11 beta HSD2, mediate cortisol-dependent nuclear translocation and transcriptional activation of MR and are responsible at least for a part of the sodium retention and potassium excretion observed in patients with biliary obstruction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12015312     DOI: 10.1074/jbc.M201556200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  DHEA induces 11 -HSD2 by acting on CCAAT/enhancer-binding proteins.

Authors:  Zoltan Balazs; Roberto A S Schweizer; Felix J Frey; Françoise Rohner-Jeanrenaud; Alex Odermatt
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

2.  Increased production of 11beta-hydroxysteroid dehydrogenase type 2 in the kidney microsomes of squirrel monkeys (Saimiri spp.).

Authors:  Patti W Sadosky; Jonathan G Scammell
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 3.  Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling?

Authors:  Marine Baptissart; Aurelie Vega; Emmanuelle Martinot; Silvère Baron; Jean-Marc A Lobaccaro; David H Volle
Journal:  Cell Mol Life Sci       Date:  2013-06-20       Impact factor: 9.261

Review 4.  11β-hydroxysteroid dehydrogenases: A growing multi-tasking family.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2021-02-17       Impact factor: 4.102

5.  The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome.

Authors:  Minghan Wang
Journal:  Nutr Metab (Lond)       Date:  2005-02-02       Impact factor: 4.169

6.  Reduced cortisol metabolism during critical illness.

Authors:  Eva Boonen; Hilke Vervenne; Philippe Meersseman; Ruth Andrew; Leen Mortier; Peter E Declercq; Yoo-Mee Vanwijngaerden; Isabel Spriet; Pieter J Wouters; Sarah Vander Perre; Lies Langouche; Ilse Vanhorebeek; Brian R Walker; Greet Van den Berghe
Journal:  N Engl J Med       Date:  2013-03-19       Impact factor: 91.245

Review 7.  Sepsis as a Pan-Endocrine Illness-Endocrine Disorders in Septic Patients.

Authors:  Weronika Wasyluk; Martyna Wasyluk; Agnieszka Zwolak
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.